Therapeutic Intervention of an Intranasally Administered Monoclonal Antibody Targeting the SARS-CoV-2 Omicron Spike Protein Against SARS-CoV-2 Omicron Infection in Mice.

IF 1.5 4区医学 Q4 IMMUNOLOGY

Viral immunology Pub Date : 2025-06-04 DOI:10.1089/vim.2024.0095

Jinsoo Kim, Suyeon Kim, Dongbum Kim, Minyoung Kim, Kyeongbin Baek, Bo Min Kang, Seungchan An, In Guk Park, Songrae Kim, Sangkyu Park, Jun Gyo Suh, Minsoo Noh, Younghee Lee, Hyung-Joo Kwon

{"title":"Therapeutic Intervention of an Intranasally Administered Monoclonal Antibody Targeting the SARS-CoV-2 Omicron Spike Protein Against SARS-CoV-2 Omicron Infection in Mice.","authors":"Jinsoo Kim, Suyeon Kim, Dongbum Kim, Minyoung Kim, Kyeongbin Baek, Bo Min Kang, Seungchan An, In Guk Park, Songrae Kim, Sangkyu Park, Jun Gyo Suh, Minsoo Noh, Younghee Lee, Hyung-Joo Kwon","doi":"10.1089/vim.2024.0095","DOIUrl":null,"url":null,"abstract":"<p><p>SARS-CoV-2 has evolved into several variants of concern, with Omicron and its subvariants currently being the most prevalent. Previously, we developed a mouse monoclonal antibody (m1E3H12 mAb) specific to the receptor binding domain of SARS-CoV-2 Omicron spike protein, and the mAb showed neutralizing activity against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB. Here, we showed that the mAb provided protection against SARS-CoV-2 Omicron infection in K18-hACE2 transgenic mice when administered intranasally. The mAb treatment reduced viral loads in both the brain and lungs. Additionally, the elevated levels of RANTES (CCL5) and MIP-3 alpha (CCL20) in the brain following SARS-CoV-2 Omicron infection showed a decreasing trend after mAb treatment. Therefore, we conclude that our mAb specific to SARS-CoV-2 Omicron spike protein has the potential to be applied as therapeutics against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viral immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/vim.2024.0095","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

SARS-CoV-2 has evolved into several variants of concern, with Omicron and its subvariants currently being the most prevalent. Previously, we developed a mouse monoclonal antibody (m1E3H12 mAb) specific to the receptor binding domain of SARS-CoV-2 Omicron spike protein, and the mAb showed neutralizing activity against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB. Here, we showed that the mAb provided protection against SARS-CoV-2 Omicron infection in K18-hACE2 transgenic mice when administered intranasally. The mAb treatment reduced viral loads in both the brain and lungs. Additionally, the elevated levels of RANTES (CCL5) and MIP-3 alpha (CCL20) in the brain following SARS-CoV-2 Omicron infection showed a decreasing trend after mAb treatment. Therefore, we conclude that our mAb specific to SARS-CoV-2 Omicron spike protein has the potential to be applied as therapeutics against SARS-CoV-2 Omicron BA.1 and its subvariants BA.5, BQ.1.1, and XBB.

查看原文本刊更多论文

靶向SARS-CoV-2组粒刺突蛋白的鼻内单克隆抗体对小鼠SARS-CoV-2组粒感染的治疗干预作用

SARS-CoV-2已经演变成几种令人关注的变体，欧米克隆及其亚变体目前最为普遍。此前，我们开发了一种针对SARS-CoV-2 Omicron刺突蛋白受体结合域的小鼠单克隆抗体（m1E3H12 mAb），该单克隆抗体对SARS-CoV-2 Omicron BA.1及其亚变体BA.5、BQ.1.1和XBB具有中和活性。在这里，我们证明单抗在K18-hACE2转基因小鼠中经鼻给药可保护其免受SARS-CoV-2组粒感染。单抗治疗降低了大脑和肺部的病毒载量。此外，SARS-CoV-2 Omicron感染后大脑中升高的RANTES （CCL5）和MIP-3 α (CCL20)水平在单抗治疗后呈下降趋势。因此，我们得出结论，我们的单抗特异性针对SARS-CoV-2 Omicron刺突蛋白，有潜力作为治疗SARS-CoV-2 Omicron BA.1及其亚变体BA.5、BQ.1.1和XBB的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Viral immunology 医学-病毒学

CiteScore

3.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Viral Immunology delivers cutting-edge peer-reviewed research on rare, emerging, and under-studied viruses, with special focus on analyzing mutual relationships between external viruses and internal immunity. Original research, reviews, and commentaries on relevant viruses are presented in clinical, translational, and basic science articles for researchers in multiple disciplines. Viral Immunology coverage includes: Human and animal viral immunology Research and development of viral vaccines, including field trials Immunological characterization of viral components Virus-based immunological diseases, including autoimmune syndromes Pathogenic mechanisms Viral diagnostics Tumor and cancer immunology with virus as the primary factor Viral immunology methods.